1. Fig. 4 Representative CT and PET/CT images of three patients with NSCLCs.
Representative CT and PET/CT images of three patients with NSCLCs. (A) Patient (number 3) with an EGFR exon 19 E746-A750 deletion who did not receive EGFR-TKI treatment, with a tumor in the upper right lobe of the lung [red arrows; 18F-MPG SUVmax (maximum standard uptake value) of 3.93]. (B) Patient (number 36) with an EGFR exon 21 L858R point mutation, 15 days after gefitinib treatment. Tumor in the upper right lung lobe (red arrows; 18F-MPG SUVmax of 3.60) and spinal metastasis (yellow arrows; 18F-MPG SUVmax of 2.11) were observed both on 18F-MPG and 18F-FDG images. (C) Patient (number 54) with wild-type EGFR who did not receive EGFR-TKI treatment. Tumor in the left hilum (red arrows; 18F-MPG SUVmax of 1.38) was prominently observed on the 18F-MPG image.
Xilin Sun et al., Sci Transl Med 2018;10:eaan8840
Published by AAAS